Theratechnologies’ Trogarzo (ibalizumab-uiyk), an antiviral medicine that prevents human immunodeficiency virus (HIV) from multiplying in your body, has been approved by the FDA for 30-Second Intravenous (IV) Push, simplifying HIV treatment for heavily treatment-experienced population.
Trogarzo is used to treat the small percentage of patients who have multidrug-resistant human immunodeficiency virus type 1 HIV (MDR HIV-1 Infection) and who have failed other HIV therapies. In a clinical trial, most patients (33 of the 40 patients, or 83%) experienced a significant decrease in their HIV-RNA levels one week after Trogarzo was added to their ineffective antiretroviral regimens.
Trogarzo is administered intravenously (IV) once every 14 days by a trained medical professional
